Mitochondrial function-improving composition
A stabilized cis-type xanthophyll composition addresses the instability issue by using emulsifiers, enabling long-term administration and improving mitochondrial function to prevent metabolic disorders and muscle dysfunction.
Patent Information
- Application Number
- PCT/JP2026/017648
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing compositions of cis-xanthophylls are unstable and difficult to maintain for long-term use due to isomerization to trans-xanthophylls, limiting their effectiveness in improving mitochondrial function and preventing metabolic disorders.
A composition containing cis-type xanthophylls stabilized with specific amounts of cis-type xanthophyll and emulsifiers like polyglycerol fatty acid esters or sucrose fatty acid esters, preventing isomerization and allowing long-term continuous administration.
The composition effectively improves mitochondrial function, preventing metabolic syndrome, muscle dysfunction, and impaired cardiac function by enhancing energy metabolism in tissues rich in mitochondria, such as skeletal and cardiac muscle.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure 00000062_0000 
Figure 00000062_0001
Abstract
Description
Composition for improving mitochondrial function
[0001] This invention relates to a composition for improving mitochondrial function. This application claims priority under Japanese Patent Application No. 2025-077830, filed in Japan on May 8, 2025, the contents of which are incorporated herein by reference.
[0002] Due to changes in modern lifestyles, the obese population is rapidly increasing worldwide. Obesity is the basis for metabolic syndrome, including type 2 diabetes, hypertension, and dyslipidemia, and is a major risk factor for future strokes, myocardial infarctions, malignant tumors, and dementia. Obesity is known to cause energy metabolism abnormalities such as insulin resistance, and preventing the progression of insulin resistance due to obesity is expected to prevent lifestyle-related diseases and greatly improve the quality of life for the public. Generally, effective means of preventing obesity include avoiding overeating, burning energy through exercise, and increasing basal metabolism to burn energy. The first two are based on individual lifestyle improvements, but these are often difficult to implement in the busy society and living environment of modern people. Furthermore, it is known that saturated fatty acids released from fat cells during obesity induce mitochondrial dysfunction, which leads to the exacerbation of insulin resistance. Moreover, mitochondrial dysfunction itself induces insulin resistance, and the two can deeply influence each other. Furthermore, during weight loss in obese individuals, it is necessary to break down lipids stored in adipose tissue into free fatty acids and burn them primarily through β-oxidation in mitochondria. Therefore, mitochondrial function is of crucial importance in exercise therapy for obesity, especially in weight loss. Consequently, there is a great expectation for groundbreaking methods to prevent the progression of insulin resistance and mitochondrial dysfunction caused by obesity in the busy social and lifestyle environments of modern people.
[0003] In addition, advanced countries including Japan are facing a progressing declining birthrate and aging population. This not only places a huge socio-economic burden due to the decrease in the working-age population and the increase in the number of people requiring long-term care, represented by bedridden individuals, but also leads to a decline in the Quality of Life (QOL) of the elderly. Frailty is a core concept addressing these issues. Frailty has physical, mental and social components, and it has been suggested that early intervention and countermeasures can reversibly improve the condition, potentially preventing progression to a state requiring long-term care. Sarcopenia is cited as a form of physical frailty. Sarcopenia refers to a condition in which aging-related loss of muscle mass and decline in muscle strength ultimately lead to reduced muscle function. The deterioration of muscle mass and muscle quality lowers the quality of daily life and may result in the need for nursing care. Accordingly, maintaining and improving muscle mass and quality through interventions such as exercise and nutritional status improvement is considered beneficial as a method for preventing and ameliorating sarcopenia. Skeletal muscle function consumes large amounts of energy. In particular, slow-twitch muscles involved in posture maintenance and fast-twitch muscles involved in instantaneous force are tissues rich in mitochondria. While the energy consumption required for muscle contraction relies on anaerobic metabolism such as the creatine phosphate system and glycolysis in the short term, aerobic metabolism via the mitochondrial electron transport chain is the primary source for endurance and related functions. Furthermore, the rephosphorylation of creatine generated by anaerobic energy production and the reuse of lactic acid produced by glycolysis take place within the mitochondria. Therefore, mitochondrial function is extremely important for the overall function of skeletal muscle, and mitochondrial activation is particularly critical for maintaining slow-twitch muscle function and sustaining endurance. Improvement of mitochondrial function, especially in the elderly, is an important factor for preventing the onset and progression of sarcopenia, and the development of pharmaceuticals and foods related to such activation is highly anticipated.
[0004] Furthermore, mitochondria are abundant not only in skeletal muscle, but also in cardiac muscle, smooth muscle, and tissues that perform aerobic metabolism. For example, a decline in mitochondrial function in cardiac muscle is thought to lead to a decline in cardiac function. Also, overuse of the ciliary muscle and iris due to adjusting vision using computers and smartphones can lead to insufficient energy supply to these tissues, resulting in impaired accommodative power and transient vision loss, as well as symptoms such as eye strain. Mitochondrial function is also extremely important in the liver and brain, which require large amounts of energy, and plays a crucial role in the utilization of fatty acids, sugars, and ketone bodies for energy. Therefore, if energy production in these organs is insufficient, it can have a significant impact on the entire body, including cognitive decline, fatigue, and metabolic abnormalities. Considering all of the above, it is expected that improving mitochondrial function throughout the body can improve the aforementioned conditions even in healthy individuals.
[0005] The mitochondrial functions described so far include the production of NADH via the β-oxidation of lipids, the tricarboxylic acid pathway of sugars and amino acids, and energy production through the electron transport chain and oxidative phosphorylation; the metabolism of lactate and ketone bodies; the suppression of reactive oxygen species production during excessive energy metabolism via uncoupling proteins, etc., as well as heat production. Furthermore, they also include the regulation of intracellular calcium ion concentration and the control of innate immunity.
[0006] Mitochondrial function is impaired by various metabolic stresses, and one of the mechanisms is the breakdown of mitochondrial quality control. Within cells, mitochondria are not only involved in their own DNA replication, but also in degradation, regeneration, fission, and fusion. These enzyme proteins form a network within the cell, maintaining their quality and function. Failure of these functions can lead to various diseases. For example, in addition to the various metabolic diseases summarized above, genetic dysfunction can cause diseases such as Parkinson's disease and mitochondrial diseases. This quality control is monitored by proteins that harm various metabolic sensors, and among them, AMPK (AMP-activated protein kinase) is known to sense intracellular ATP levels and environmental factors, contribute to the induction of various transcription factors, and regulate the activity of the aforementioned quality control proteins. The activity of the various transcription factors described here is regulated by the nuclear receptor PPAR (Peroxisome Proliferator-Activated Receptor) and its cofactor PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha).
[0007] Drugs and candidate compounds targeting these proteins that improve mitochondrial function already exist for therapeutic purposes. For example, the mechanism of action of biguanoid compounds such as metformin and imeglimin is thought to be AMPK activation. Thiazolidinedione compounds mainly activate PPARγ in adipose tissue, while fibrate compounds mainly activate PPARα in the liver. In recent years, compounds that activate PPARβ / δ have shown promise for their effects on metabolic dysfunction-associated steatohepatitis (MASH) and sarcopenia. To elaborate, these nuclear transcription factors regulate the expression of downstream mitochondrial-related genes by coupling with RAR (retinoic acid receptor: All-Trans retinoic acid receptor) and RXR (retinoid X receptor: 9-cis retinoic acid is the ligand), which use retinoic acid-related compounds, the active component of vitamin A which is an enzymatic breakdown product of β-carotene, as ligands.
[0008] As shown above, mitochondrial function activators have been shown to improve energy metabolism, and therefore it can be inferred that they exert their pharmacological effects by improving the metabolic and immune functions of biological tissues.
[0009] Carotenoids are pigments that are widely found in nature. Among carotenoids, xanthophylls, which contain an oxygen atom, have strong antioxidant activity and various other excellent effects in lipid bilayers, and are therefore used in a wide range of applications such as health foods, cosmetics, and food colorings. In particular, β-cryptoxanthin, which has provitamin A activity related to retinoic acid, as well as non-provitamin A carotenoids such as capsanthin, capsorbin, fucoxanthin, and astaxanthin, are thought to coexist in membrane lipids such as mitochondria due to their amphiphilic properties. Therefore, based on their localization, these xanthophylls are thought to be able to protect mitochondria from reactive oxygen species damage caused by excess energy. Furthermore, they are known to improve glucose uptake and lipid utilization in skeletal muscle through the expression of the aforementioned transcription factors and enzymes, and to show effects that improve blood glucose levels and blood lipids. In addition, it has been suggested that they may be useful in treating sarcopenia by improving skeletal muscle mass and function.
[0010] Xanthophylls such as β-cryptoxanthin, zeaxanthin, lutein, capsanthin, capsorbin, fucoxanthin, amarauciaxanthin A, fucoxanthinol, and astaxanthin generally exist primarily in their all-trans form in nature, where all conjugated double bonds in the polyene portion of the molecule are in the trans isomer. In recent years, it has become increasingly clear that cis-type xanthophylls have higher bioavailability and accumulation in the body than all-trans-type xanthophylls, and independently exhibit greater diverse physiological activities such as antioxidant, anti-inflammatory, and skin-improving effects, leading to increased attention on their intake.
[0011] For example, among xanthophylls, β-cryptoxanthin, capsanthin, capsorbin, fucoxanthin, amarociaxanthin A, fucoxanthinol, and astaxanthin are known to have metabolic-improving and muscle-atrophy-inhibiting effects in adipose tissue and skeletal muscle tissue, which is the largest energy-consuming organ.
[0012] In particular, astaxanthin is expected to have a stronger effect due to its strong antioxidant activity. However, although astaxanthin is known to activate mitochondria in skeletal muscle, its physiological effects are only effective at concentrations of 25 μM or higher, and there is a desire for superior effects at lower doses. Furthermore, trans-astaxanthin is known to have poor tissue penetration, and higher doses and longer durations of intake were necessary to fully exert its medicinal effects.
[0013] Patent Document 1 discloses an invention relating to the skin-improving effect of cis-type carotenoids against ultraviolet light.
[0014] Patent document 2 discloses a stable emulsified composition of cis-type carotenoids.
[0015] Japanese Patent Publication No. 2023-167797, International Publication No. 2023 / 120618
[0016] However, there have been no reports on the mitochondrial function-improving effects of cis-xanthophylls. Furthermore, while cis-xanthophylls exist naturally as a subset of trans-xanthophylls, and the cis-isomer ratio remains constant and stable in vivo, once extracted, they readily isomerize from cis-xanthophylls to all trans-xanthophylls. Therefore, maintaining and preserving the cis-xanthophylls stably is difficult, and preparation is required each time cis-xanthophylls are taken. Consequently, it is difficult to manufacture and portion out cis-xanthophylls for long-term use of two days or more, which remains a challenge that needs to be addressed in industrialization.
[0017] The present invention has been made in view of these circumstances, and aims to provide a composition, a food, a pharmaceutical, or a cosmetic containing the composition, that can improve or prevent metabolic syndrome, muscle dysfunction, impaired eye accommodation, and impaired cardiac function associated with energy metabolism disorders by improving energy metabolism in tissues rich in mitochondrial energy supply, including skeletal muscle and cardiac muscle. The invention also aims to provide a cis-xanthophyll composition that improves mitochondrial function and can be administered continuously for a long period of time.
[0018] The inventors of this invention have conducted thorough research on the above-mentioned problems and have found that a composition containing cis-type xanthophyll improves glucose uptake in skeletal muscle, has an effect of improving blood glucose levels, and consequently has the effect of preventing the progression of insulin resistance due to obesity, thus completing the present invention. Furthermore, they have found that by coexisting a specific amount of cis-type xanthophyll with cis-type xanthophyll, which is unstable when used alone, especially when trans-type is present, or by creating an emulsified composition containing cis-type xanthophyll with a cis-type content of 40% by mass or more relative to the total cis-type and trans-type, and at least one selected from the group consisting of polyglycerol fatty acid esters and sucrose fatty acid esters, the isomerization of all cis-type xanthophyll to the trans-type isomer is suppressed, making long-term continuous administration possible.
[0019] The present invention has the following aspects: [1] A composition for improving mitochondrial function containing cis-type xanthophyll. [2] The composition for improving mitochondrial function according to [1], wherein the cis-type xanthophyll is one or more of the following (a) to (j). (a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives [3] The cis-lutein derivative comprises one or more cis-lutein derivatives selected from the group consisting of lipid esters of cis-lutein, glycosides of cis-lutein, fatty acid glycosides of cis-lutein, aliphatic ethers of cis-lutein, and sulfate esters of cis-lutein, as described in [2]. [4] The cis-lutein derivative comprises a lipid ester of cis-lutein, as described in [2]. [5] The cis-lutein derivative comprises a lipid ester of cis-lutein, as described in [2].[6] The mitochondrial function improving composition according to [2], wherein the cis-type zeaxanthin derivative comprises one or more cis-type zeaxanthin derivatives selected from the group consisting of lipid esters of cis-type zeaxanthin, glycosides of cis-type zeaxanthin, fatty acid glycosides of cis-type zeaxanthin, aliphatic ethers of cis-type zeaxanthin, and sulfate esters of cis-type zeaxanthin. [7] The mitochondrial function improving composition according to [2], wherein the cis-type zeaxanthin derivative comprises a lipid ester of cis-type zeaxanthin. [8] The mitochondrial function improving composition according to [2], wherein the cis-type zeaxanthin derivative comprises a lipid ester of cis-type zeaxanthin and one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid. [9] The cis-type meso-zeaxanthin derivative comprises one or more cis-type zeaxanthin derivatives selected from the group consisting of lipid esters of cis-type meso-zeaxanthin, glycosides of cis-type meso-zeaxanthin, fatty acid glycosides of cis-type meso-zeaxanthin, aliphatic ethers of cis-type meso-zeaxanthin, and sulfate esters of cis-type meso-zeaxanthin, as described in [2].
[10] The cis-type meso-zeaxanthin derivative comprises a lipid ester of cis-type meso-zeaxanthin, as described in [2].
[11] The composition for improving mitochondrial function according to [2], wherein the cis-type meso-zeaxanthin derivative comprises a lipid ester of cis-type meso-zeaxanthin with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[12] The mitochondrial function improving composition according to [2], wherein the cis-type astaxanthin derivative comprises one or more cis-type astaxanthin derivatives selected from the group consisting of lipid esters of cis-type astaxanthin, glycosides of cis-type astaxanthin, fatty acid glycosides of cis-type astaxanthin, aliphatic ethers of cis-type astaxanthin, and sulfate esters of cis-type astaxanthin.
[13] The mitochondrial function improving composition according to [2], wherein the cis-type astaxanthin derivative comprises a lipid ester of cis-type astaxanthin.
[14] The mitochondrial function improving composition according to [2], wherein the cis-type astaxanthin derivative comprises a lipid ester of cis-type astaxanthin and one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[15] The cis-type β-cryptoxanthin composition according to [2], wherein the cis-type β-cryptoxanthin comprises one or more cis-type β-cryptoxanthin selected from the group consisting of lipid esters of cis-type β-cryptoxanthin, glycosides of cis-type β-cryptoxanthin, fatty acid glycosides of cis-type β-cryptoxanthin, aliphatic ethers of cis-type β-cryptoxanthin, and sulfate esters of cis-type β-cryptoxanthin.
[16] The cis-type β-cryptoxanthin composition according to [2], wherein the cis-type β-cryptoxanthin comprises lipid esters of cis-type β-cryptoxanthin.
[17] The composition for improving mitochondrial function according to [2], wherein the cis-type β-cryptoxanthin comprises a lipid ester of cis-type β-cryptoxanthin with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[18] The mitochondrial function improving composition according to [2], wherein the cis-capsanthin comprises one or more cis-capsanthin selected from the group consisting of lipid esters of cis-capsanthin, glycosides of cis-capsanthin, fatty acid glycosides of cis-capsanthin, aliphatic ethers of cis-capsanthin, and sulfate esters of cis-capsanthin.
[19] The mitochondrial function improving composition according to [2], wherein the cis-capsanthin comprises a lipid ester of cis-capsanthin.
[20] The mitochondrial function improving composition according to [2], wherein the cis-capsanthin comprises a lipid ester of cis-capsanthin and one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[21] The mitochondrial function improving composition according to [2], wherein the cis-type capsorbin comprises one or more cis-type capsorbins selected from the group consisting of lipid esters of cis-type capsorbin, glycosides of cis-type capsorbin, fatty acid glycosides of cis-type capsorbin, aliphatic ethers of cis-type capsorbin, and sulfate esters of cis-type capsorbin.
[22] The mitochondrial function improving composition according to [2], wherein the cis-type capsorbin comprises a lipid ester of cis-type capsorbin.
[23] The mitochondrial function improving composition according to [2], wherein the cis-type capsorbin comprises a lipid ester of cis-type capsorbin and one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[24] The composition for improving mitochondrial function according to [2], wherein the cis-type fucoxanthin comprises one or more cis-type fucoxanthin selected from the group consisting of lipid esters of cis-type fucoxanthin, glycosides of cis-type fucoxanthin, fatty acid glycosides of cis-type fucoxanthin, aliphatic ethers of cis-type fucoxanthin, and sulfate esters of cis-type fucoxanthin.
[25] The composition for improving mitochondrial function according to [2], wherein the cis-type fucoxanthin comprises lipid esters of cis-type fucoxanthin.
[26] The composition for improving mitochondrial function according to [2], wherein the cis-type fucoxanthin comprises a lipid ester of cis-type fucoxanthin with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[27] The composition for improving mitochondrial function according to [2], wherein the cis-type amarouciaxanthin A comprises one or more cis-type amarouciaxanthin A selected from the group consisting of a lipid ester of cis-type amarouciaxanthin A, a glycoside of cis-type amarouciaxanthin A, a fatty acid glycoside of cis-type amarouciaxanthin A, an aliphatic ether of cis-type amarouciaxanthin A, and a sulfate ester of cis-type amarouciaxanthin A.
[28] The composition for improving mitochondrial function according to [2], wherein the cis-type amarouciaxanthin A comprises a lipid ester of cis-type amarouciaxanthin A.
[29] The composition for improving mitochondrial function according to [2], wherein the cis-type amarouciaxanthin A comprises a lipid ester of cis-type amarouciaxanthin A with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[30] The composition for improving mitochondrial function according to [2], wherein the cis-type fucoxanthinol comprises one or more cis-type fucoxanthinols selected from the group consisting of lipid esters of cis-type fucoxanthinol, glycosides of cis-type fucoxanthinol, fatty acid glycosides of cis-type fucoxanthinol, aliphatic ethers of cis-type fucoxanthinol, and sulfate esters of cis-type fucoxanthinol.
[31] The composition for improving mitochondrial function according to [2], wherein the cis-type fucoxanthinol comprises lipid esters of cis-type fucoxanthinol.
[32] The mitochondrial function improving composition according to [2], wherein the cis-type fucoxanthinol comprises a lipid ester of cis-type fucoxanthinol with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
[33] The mitochondrial function improving composition according to any one of [1] to
[32] , used to improve or prevent the progression of insulin resistance due to obesity.
[34] The mitochondrial function improving composition according to
[33] , wherein the insulin resistance is due to sarcopenic obesity, subcutaneous fat obesity, or visceral fat obesity.
[35] The mitochondrial function improving composition according to
[33] , wherein the improvement or prevention of the progression of insulin resistance is due to improved glucose uptake in skeletal muscle and an improvement in blood glucose levels.
[36] A food, pharmaceutical, or cosmetic containing the mitochondrial function improving composition according to any one of [1] to
[35] . A method for producing a food, pharmaceutical, or cosmetic, comprising the step of producing a mitochondrial function improving composition described in any one of the items
[37] [1] to
[36] .
[0020] According to the present invention, by improving energy metabolism in tissues rich in mitochondrial energy supply, including skeletal muscle and cardiac muscle, it is possible to provide a composition that can improve or prevent metabolic syndrome, decreased muscle function, impaired eye accommodation, and decreased cardiac function associated with energy metabolism disorders, as well as a food, pharmaceutical, or cosmetic containing the composition.
[0021] Figure showing the chromatogram of cis-astaxanthin after ester hydrolysis. Figure showing the blood pharmacokinetics of cis-astaxanthin ester. Figure showing the effects of cis- and trans-astaxanthin on gene expression in skeletal muscle. Figure showing the effects of cis- and trans-astaxanthin on gene expression in mouse calf muscle. Figure showing the effects of cis- and trans-astaxanthin on muscle fiber gene expression in mouse calf muscle. Figure showing the effects of cis- and trans-astaxanthin on mouse muscle function.
[0022] (Composition for improving mitochondrial function) The composition for improving mitochondrial function of this embodiment contains cis-xanthophyll. Xanthophyll is a type of carotenoid, and many compounds are known, such as lutein, zeaxanthin, β-cryptoxanthin, α-cryptoxanthin, capsanthin, capsorbin, and astaxanthin. Xanthophyll has a structure consisting of a polyene moiety made up of a conjugated double bond between multiple carbon atoms, end groups modified at both ends, and an oxygen atom such as an alcohol, ketone, or epoxy within the molecule.
[0023] The cis-type xanthophyll is preferably one or more of the following (a) to (j). (a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives
[0024] (a) cis lutein, (b) cis zeaxanthin, (c) cis meso-zeaxanthin, (d) cis astaxanthin, (e) cis β-cryptoxanthin, (f) cis capsanthin, (g) cis capsorbin, (h) cis fucoxanthin, (i) cis amarociaxanthin, and (j) cis fucoxanthinol refer to the free form in which all hydroxyl groups in these compounds have not been derivatized by esterification or other means.
[0025] <(a) Cis-type lutein and / or cis-type lutein derivatives> <Cis-type lutein> Cis-type lutein consists of a polyene chain made up of 10 conjugated double bonds and end groups attached to both ends. In this specification, isomers in which at least one of the 10 conjugated double bonds of the polyene chain is in the cis type are referred to as cis-type lutein, and isomers in which all are in the trans type are referred to as all-trans type lutein.
[0026] ≪Cis-Lutein Derivatives≫ Examples of cis-lutein derivatives include lipid esters of cis-lutein, glycosides of cis-lutein, fatty acid glycosides of cis-lutein, aliphatic ethers of cis-lutein, and sulfate esters of cis-lutein.
[0027] The lipids (fatty acids) in the lipid esters of cis-lutein include acetic acid, propionic acid, butyric acid, crotonic acid, valeric acid, isovaleric acid, caproic acid, enanthic acid, caprylic acid, peragolic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, myristoleic acid, pentadecylic acid, palmitic acid, sapienic acid, palmitoleic acid, margaric acid, pinolenic acid, stearic acid, sevaleic acid, oleic acid, linoleic acid, and eleostearic acid. Examples include acids, α-linolenic acid, γ-linolenic acid, stearidonic acid, calendic acid, vaccenic acid, pauric acid, elaidic acid, gadolic acid, eicosenoic acid, arachidic acid, meadic acid, dihomo-γ-linolenic acid, eicosatrienoic acid, eicosapentaenoic acid, arachidonic acid, behenic acid, erucic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, lignoceric acid, nervonic acid, tetracosapentaenoic acid, tetracosahexaenoic acid, cerotic acid, montanic acid, melissic acid, etc. Preferably, the lipids (fatty acids) include caprylic acid, capric acid, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, stearidonic acid, calendic acid, vaccenic acid, pauric acid, elaidic acid, eicosenoic acid, arachidic acid, dihomo-gamma-linolenic acid, eicosatrienoic acid, eicosapentaenoic acid, arachidonic acid, behenic acid, erucic acid, elaidic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, etc. Preferably, the following are used: caprylic acid, capric acid, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, elaidic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid. More preferably, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid, arachidonic acid, elaidic acid, and docosahexaenoic acid.
[0028] The lipid ester of cis-lutein may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-lutein is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-lutein, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-lutein is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0029] - Glycosides of cis-lutein Examples of glycosides of cis-lutein include glucose, xylose, arabinose, mannose, fucose, fructose, galactose, and polysaccharides containing these, preferably fucose, xylose, and glucose, and more preferably glucose.
[0030] The glycoside of cis-lutein may be composed of a mixture of multiple glycosides of cis-lutein. In the mixture, the molar ratio of the glycoside to cis-lutein is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of glycosides of cis-lutein, the molar ratio of fucose, xylose, lactose, and glucose to cis-lutein is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0031] • Fatty acid glycosides of cis-lutein: Examples of fatty acid glycosides in cis-lutein fatty acid glycosides include glucose fatty acid esters. The cis-lutein fatty acid glycoside may be composed of a mixture of multiple cis-lutein fatty acid glycosides.
[0032] Aliphatic ethers of cis-lutein: Examples of aliphatic ethers of cis-lutein include generally known aliphatic ethers of cis-lutein. An aliphatic ether of cis-lutein may be composed of a mixture of multiple aliphatic ethers of cis-lutein.
[0033] • Sulfate esters of cis-lutein: Examples of sulfate esters of cis-lutein include generally known sulfate esters of cis-lutein. Sulfate esters of cis-lutein may be composed of a mixture of multiple sulfate esters of cis-lutein.
[0034] <(b) Cis-type zeaxanthin and / or cis-type zeaxanthin derivatives> <Cis-type zeaxanthin> Cis-type zeaxanthin ((3R,3'R)-β,β-Carotene-3,3'-diol) is composed of a polyene chain consisting of 11 conjugated double bonds and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond of the polyene chain are referred to as cis-type zeaxanthin, and isomers in which all are trans-type are referred to as all-trans-type zeaxanthin.
[0035] ≪Cis-type zeaxanthin derivatives≫ Examples of cis-type zeaxanthin derivatives include lipid esters of cis-type zeaxanthin, glycosides of cis-type zeaxanthin, fatty acid glycosides of cis-type zeaxanthin, aliphatic ethers of cis-type zeaxanthin, and sulfate esters of cis-type zeaxanthin.
[0036] ・Lipid esters of cis-type zeaxanthin The lipids (fatty acids) in the lipid esters of cis-type zeaxanthin are the same lipids as those in the lipid esters of cis-type lutein described above. The lipid esters of cis-type zeaxanthin may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-type zeaxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-type zeaxanthin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-type zeaxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0037] ・Cis-Zeaxanthin Glycosides The glycosides in cis-zeaxanthin glycosides are the same as the glycosides in cis-lutein glycosides described above. The cis-zeaxanthin glycoside may be composed of a mixture of multiple cis-zeaxanthin glycosides. In such a mixture, the molar ratio of the glycoside to cis-zeaxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-zeaxanthin glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-zeaxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0038] • Fatty acid glycosides of cis-zeaxanthin: Examples of fatty acid glycosides in cis-zeaxanthin fatty acid glycosides include glucose fatty acid esters. The fatty acid glycoside of cis-zeaxanthin may be composed of a mixture of multiple fatty acid glycosides of cis-zeaxanthin.
[0039] Aliphatic ethers of cis-type zeaxanthin: Examples of aliphatic ethers of cis-type zeaxanthin include generally known aliphatic ethers of cis-type zeaxanthin. An aliphatic ether of cis-type zeaxanthin may be composed of a mixture of multiple aliphatic ethers of cis-type zeaxanthin.
[0040] • Sulfate esters of cis-type zeaxanthin Examples of sulfate esters of cis-type zeaxanthin include generally known sulfate esters of cis-type zeaxanthin. Sulfate esters of cis-type zeaxanthin may be composed of a mixture of multiple sulfate esters of cis-type zeaxanthin.
[0041] <(c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives> <<Cis-type meso-zeaxanthin>> Cis-type meso-zeaxanthin ((3R,3'S)-β,β-Carotene-3,3'-diol) is composed of a polyene chain consisting of 11 conjugated double bonds and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond of the polyene chain are referred to as cis-type meso-zeaxanthin, and isomers in which all are trans-type are referred to as all-trans-type meso-zeaxanthin.
[0042] ≪Cis-type meso-zeaxanthin derivatives≫ Examples of cis-type meso-zeaxanthin derivatives include lipid esters of cis-type meso-zeaxanthin, glycosides of cis-type meso-zeaxanthin, fatty acid glycosides of cis-type meso-zeaxanthin, aliphatic ethers of cis-type meso-zeaxanthin, and sulfate esters of cis-type meso-zeaxanthin.
[0043] - Lipid ester of cis-meso-zeaxanthin Examples of the lipid (fatty acid) in the lipid ester of cis-meso-zeaxanthin include the same lipids as those in the aforementioned lipid ester of cis-lutein. The lipid ester of cis-meso-zeaxanthin may be composed of a mixture of a plurality of lipid esters. In the mixture, the molar ratio of the lipid to cis-meso-zeaxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, still more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in the mixture of lipid esters of cis-meso-zeaxanthin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid and docosahexaenoic acid to cis-meso-zeaxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, still more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0044] - Glycoside of cis-meso-zeaxanthin Examples of the glycoside in the glycoside of cis-meso-zeaxanthin include the same glycosides as those in the aforementioned glycoside of cis-lutein. The glycoside of cis-meso-zeaxanthin may be composed of a mixture of a plurality of glycosides of cis-meso-zeaxanthin. In the mixture, the molar ratio of the glycoside to cis-meso-zeaxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, still more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in the mixture of glycosides of cis-meso-zeaxanthin, the molar ratio of fucose, xylose, lactose and glucose to cis-meso-zeaxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, still more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0045] ・Fatty acid glycoside of cis-meso-zeaxanthin Examples of the fatty acid glycoside in the fatty acid glycoside of cis-meso-zeaxanthin include glucose fatty acid esters and the like. The fatty acid glycoside of cis-meso-zeaxanthin may be composed of a mixture of a plurality of fatty acid glycosides of cis-meso-zeaxanthin.
[0046] ・Aliphatic ether derivative of cis-meso-zeaxanthin Examples of the aliphatic ether derivative of cis-meso-zeaxanthin include conventionally known aliphatic ether derivatives of cis-meso-zeaxanthin. The aliphatic ether derivative of cis-meso-zeaxanthin may be composed of a mixture of a plurality of aliphatic ether derivatives of cis-meso-zeaxanthin.
[0047] ・Sulfate ester of cis-meso-zeaxanthin Examples of the sulfate ester of cis-meso-zeaxanthin include conventionally known sulfate esters of cis-meso-zeaxanthin. The sulfate ester of cis-meso-zeaxanthin may be composed of a mixture of a plurality of sulfate esters of cis-meso-zeaxanthin.
[0048] <(d) Cis-astaxanthin and / or cis-astaxanthin derivative> <<Cis-astaxanthin>> Cis-astaxanthin is composed of a conjugated system comprising a polyene chain consisting of 11 conjugated double bonds and end groups (terminal groups) containing keto groups attached to both ends thereof. In the present specification, an isomer containing at least one cis form among the 11 conjugated double bonds of the carbon polyene chain is referred to as cis-astaxanthin, and an isomer in which all of the double bonds are in the trans form is referred to as all-trans astaxanthin.
[0049] <<Cis-astaxanthin derivative>> Examples of the cis-astaxanthin derivative include lipid esters of cis-astaxanthin, glycosides of cis-astaxanthin, fatty acid glycosides of cis-astaxanthin, aliphatic ether derivatives of cis-astaxanthin, sulfate esters of cis-astaxanthin, and the like.
[0050] ・Lipid esters of cis-type astaxanthin The lipids (fatty acids) in the lipid esters of cis-type astaxanthin are the same lipids as those in the lipid esters of cis-type lutein described above. The lipid esters of cis-type astaxanthin may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-type astaxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-type astaxanthin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-type astaxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0051] ・Cis-astaxanthin glycosides The glycosides in cis-astaxanthin glycosides are the same as the glycosides in cis-lutein glycosides described above. The cis-astaxanthin glycoside may be composed of a mixture of multiple cis-astaxanthin glycosides. In such a mixture, the molar ratio of the glycoside to cis-astaxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-astaxanthin glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-astaxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0052] • Fatty acid glycosides of cis-astaxanthin: Examples of fatty acid glycosides in cis-astaxanthin fatty acid glycosides include glucose fatty acid esters. The fatty acid glycoside of cis-astaxanthin may be composed of a mixture of multiple fatty acid glycosides of cis-astaxanthin.
[0053] Aliphatic ethers of cis-astaxanthin: Examples of aliphatic ethers of cis-astaxanthin include generally known aliphatic ethers of cis-astaxanthin. An aliphatic ether of cis-astaxanthin may be composed of a mixture of multiple aliphatic ethers of cis-astaxanthin.
[0054] • Sulfate esters of cis-type astaxanthin Examples of sulfate esters of cis-type astaxanthin include generally known sulfate esters of cis-type astaxanthin. Sulfate esters of cis-type astaxanthin may be composed of a mixture of multiple sulfate esters of cis-type astaxanthin.
[0055] <(e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives> <<Cis-type β-cryptoxanthin>> Cis-type β-cryptoxanthin consists of a polyene chain made up of 11 conjugated double bonds and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond are referred to as cis-type β-cryptoxanthin, and isomers in which all are trans-type are referred to as all-trans-type β-cryptoxanthin.
[0056] <<Cis-type β-cryptoxanthin derivatives>> Examples of cis-type β-cryptoxanthin derivatives include lipid esters of cis-type β-cryptoxanthin, glycosides of cis-type β-cryptoxanthin, fatty acid glycosides of cis-type β-cryptoxanthin, aliphatic ethers of cis-type β-cryptoxanthin, and sulfate esters of cis-type β-cryptoxanthin.
[0057] • Lipid esters of cis-type β-cryptoxanthin The lipids (fatty acids) in the lipid esters of cis-type β-cryptoxanthin are the same lipids as those in the lipid esters of cis-type lutein described above. The lipid esters of cis-type β-cryptoxanthin may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-type β-cryptoxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a lipid ester mixture of cis-β-cryptoxanthin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-β-cryptoxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0058] ・Cis-β-cryptoxanthin glycosides The glycosides in cis-β-cryptoxanthin glycosides include the same glycosides as those in cis-lutein glycosides described above. Cis-β-cryptoxanthin glycosides may be composed of a mixture of multiple cis-β-cryptoxanthin glycosides. In such mixtures, the molar ratio of the glycoside to cis-β-cryptoxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-β-cryptoxanthin glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-β-cryptoxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0059] • Fatty acid glycosides of cis-β-cryptoxanthin Examples of fatty acid glycosides in cis-β-cryptoxanthin fatty acid glycosides include glucose fatty acid esters. The fatty acid glycoside of cis-β-cryptoxanthin may be composed of a mixture of multiple fatty acid glycosides of cis-β-cryptoxanthin.
[0060] Aliphatic ethers of cis-β-cryptoxanthin: Examples of aliphatic ethers of cis-β-cryptoxanthin include generally known aliphatic ethers of cis-β-cryptoxanthin. An aliphatic ether of cis-β-cryptoxanthin may be composed of a mixture of multiple aliphatic ethers of cis-β-cryptoxanthin.
[0061] • Sulfate esters of cis-type β-cryptoxanthin Examples of sulfate esters of cis-type β-cryptoxanthin include generally known sulfate esters of cis-type β-cryptoxanthin. Sulfate esters of cis-type β-cryptoxanthin may be composed of a mixture of multiple sulfate esters of cis-type β-cryptoxanthin.
[0062] <(f) Cis-type capsanthin and / or cis-type capsanthin derivatives> <Cis-type capsanthin> Cis-type capsanthin consists of a polyene chain made up of 11 conjugated double bonds and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond are referred to as cis-type capsanthin, and isomers in which all are trans-type are referred to as all-trans-type capsanthin.
[0063] <<Cis-type capsanthin derivatives>> Examples of cis-type capsanthin derivatives include lipid esters of cis-type capsanthin, glycosides of cis-type capsanthin, fatty acid glycosides of cis-type capsanthin, aliphatic ethers of cis-type capsanthin, and sulfate esters of cis-type capsanthin.
[0064] ・Lipid esters of cis-capsanthin The lipids (fatty acids) in the lipid esters of cis-capsanthin are the same lipids as those in the lipid esters of cis-lutein described above. The lipid esters of cis-capsanthin may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-capsanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-capsanthin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-capsanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0065] ・Cis-capsanthin glycosides The glycosides in cis-capsanthin glycosides are the same as the glycosides in cis-lutein glycosides described above. The cis-capsanthin glycoside may be composed of a mixture of multiple cis-capsanthin glycosides. In such a mixture, the molar ratio of the glycoside to cis-capsanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-capsanthin glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-capsanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0066] • Fatty acid glycosides of cis-capsanthin Examples of fatty acid glycosides in cis-capsanthin fatty acid glycosides include glucose fatty acid esters. The fatty acid glycosides of cis-capsanthin may be composed of a mixture of multiple fatty acid glycosides of cis-capsanthin.
[0067] Aliphatic ethers of cis-capsanthin: Examples of aliphatic ethers of cis-capsanthin include generally known aliphatic ethers of cis-capsanthin. An aliphatic ether of cis-capsanthin may be composed of a mixture of multiple aliphatic ethers of cis-capsanthin.
[0068] • Sulfate esters of cis-capsanthin Examples of sulfate esters of cis-capsanthin include generally known sulfate esters of cis-capsanthin. Sulfate esters of cis-capsanthin may be composed of a mixture of multiple sulfate esters of cis-capsanthin.
[0069] <(g) cis-type capsorbin and / or cis-type capsorbin derivatives> <<Cis-type capsorbin>> Cis-type capsorbin consists of a polyene chain made up of 11 conjugated double bonds and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond are referred to as cis-type capsorbin, and isomers in which all are trans-type are referred to as all-trans-type capsorbin.
[0070] ≪Cis-type capsorbin derivatives≫ Examples of cis-type capsorbin derivatives include lipid esters of cis-type capsorbin, glycosides of cis-type capsorbin, fatty acid glycosides of cis-type capsorbin, aliphatic ethers of cis-type capsorbin, and sulfate esters of cis-type capsorbin.
[0071] ・Lipid esters of cis-capsorbin The lipids (fatty acids) in the lipid esters of cis-capsorbin are the same lipids as those in the lipid esters of cis-lutein described above. The lipid esters of cis-capsorbin may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-capsorbin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-capsorbin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-capsorbin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0072] ・Cis-capsorbin glycosides The glycosides in cis-capsorbin glycosides include the same glycosides as those in cis-lutein glycosides described above. The cis-capsorbin glycoside may be composed of a mixture of multiple cis-capsorbin glycosides. In such a mixture, the molar ratio of the glycoside to cis-capsorbin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-capsorbin glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-capsorbin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0073] • Fatty acid glycosides of cis-capsorbin Examples of fatty acid glycosides in cis-capsorbin fatty acid glycosides include glucose fatty acid esters. The fatty acid glycoside of cis-capsorbin may be composed of a mixture of multiple fatty acid glycosides of cis-capsorbin.
[0074] Aliphatic ethers of cis-capsorbin: Examples of aliphatic ethers of cis-capsorbin include generally known aliphatic ethers of cis-capsorbin. An aliphatic ether of cis-capsorbin may be composed of a mixture of multiple aliphatic ethers of cis-capsorbin.
[0075] • Sulfate esters of cis-type capsorbine Examples of sulfate esters of cis-type capsorbine include generally known sulfate esters of cis-type capsorbine. Sulfate esters of cis-type capsorbine may be composed of a mixture of multiple sulfate esters of cis-type capsorbine.
[0076] <(h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives> <<Cis-type fucoxanthin>> Cis-type fucoxanthin consists of a polyene chain with nine conjugated double bonds and an allene structure, and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond are referred to as cis-type fucoxanthin, and isomers in which all are trans-type are referred to as all-trans-type fucoxanthin.
[0077] ≪Cis-type fucoxanthin derivatives≫ Examples of cis-type fucoxanthin derivatives include lipid esters of cis-type fucoxanthin, glycosides of cis-type fucoxanthin, fatty acid glycosides of cis-type fucoxanthin, aliphatic ethers of cis-type fucoxanthin, and sulfate esters of cis-type fucoxanthin.
[0078] ・Lipid esters of cis-fucoxanthin The lipids (fatty acids) in the lipid esters of cis-fucoxanthin are the same lipids as those in the lipid esters of cis-lutein described above. The lipid esters of cis-fucoxanthin may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-fucoxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-fucoxanthin, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-fucoxanthin is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0079] ・Cis-fucoxanthin glycosides The glycosides in cis-fucoxanthin glycosides are the same as the glycosides in cis-lutein glycosides described above. The cis-fucoxanthin glycoside may be composed of a mixture of multiple cis-fucoxanthin glycosides. In the mixture, the molar ratio of the glycoside to cis-fucoxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-fucoxanthin glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-fucoxanthin is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0080] • Fatty acid glycosides of cis-fucoxanthin Examples of fatty acid glycosides in cis-fucoxanthin fatty acid glycosides include glucose fatty acid esters. The fatty acid glycoside of cis-fucoxanthin may be composed of a mixture of multiple fatty acid glycosides of cis-fucoxanthin.
[0081] Aliphatic ethers of cis-fucoxanthin: Examples of aliphatic ethers of cis-fucoxanthin include generally known aliphatic ethers of cis-fucoxanthin. An aliphatic ether of cis-fucoxanthin may be composed of a mixture of multiple aliphatic ethers of cis-fucoxanthin.
[0082] • Sulfate esters of cis-fucoxanthin Examples of sulfate esters of cis-fucoxanthin include generally known sulfate esters of cis-fucoxanthin. Sulfate esters of cis-fucoxanthin may be composed of a mixture of multiple sulfate esters of cis-fucoxanthin.
[0083] <(i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives> <<Cis-type amarouciaxanthin A>> Cis-type amarouciaxanthin A consists of a polyene chain comprising nine conjugated double bonds and an allene structure, and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond are referred to as cis-type amarouciaxanthin A, and isomers in which all are trans-type are referred to as all-trans-type amarouciaxanthin A.
[0084] <<Cis-type amarouciaxanthin A derivatives>> Examples of cis-type amarouciaxanthin A derivatives include lipid esters of cis-type amarouciaxanthin A, glycosides of cis-type amarouciaxanthin A, fatty acid glycosides of cis-type amarouciaxanthin A, aliphatic ethers of cis-type amarouciaxanthin A, and sulfate esters of cis-type amarouciaxanthin A.
[0085] - Lipid ester of cis-type amarouciaxanthin A The lipids (fatty acids) in the lipid ester of cis-type amarouciaxanthin A are the same lipids as those in the lipid ester of cis-type lutein described above. The lipid ester of cis-type amarouciaxanthin A may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-type amarouciaxanthin A is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a lipid ester mixture of cis-type amarouciaxanthin A, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-type amarouciaxanthin A is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0086] - Glycosides of cis-type amarouciaxanthin A The glycosides in the glycosides of cis-type amarouciaxanthin A are the same glycosides as those in the glycosides of cis-type lutein described above. The glycosides of cis-type amarouciaxanthin A may be composed of a mixture of multiple glycosides of cis-type amarouciaxanthin A. In the mixture, the molar ratio of the glycoside to cis-type amarouciaxanthin A is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a glycoside mixture of cis-amarouciaxanthin A, the molar ratio of fucose, xylose, lactose, and glucose to cis-amarouciaxanthin A is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0087] • Fatty acid glycosides of cis-amarouciaxanthin A Examples of fatty acid glycosides in cis-amarouciaxanthin A include glucose fatty acid esters. The fatty acid glycoside of cis-amarouciaxanthin A may be composed of a mixture of multiple fatty acid glycosides of cis-amarouciaxanthin A.
[0088] Aliphatic ether forms of cis-type amarouciaxanthin A: Examples of aliphatic ether forms of cis-type amarouciaxanthin A include generally known aliphatic ether forms of cis-type amarouciaxanthin A. An aliphatic ether form of cis-type amarouciaxanthin A may be composed of a mixture of multiple aliphatic ether forms of cis-type amarouciaxanthin A.
[0089] ・Sulfate esters of cis-type amarouciaxanthin A Examples of sulfate esters of cis-type amarouciaxanthin A include generally known sulfate esters of cis-type amarouciaxanthin A. Sulfate esters of cis-type amarouciaxanthin A may be composed of a mixture of multiple sulfate esters of cis-type amarouciaxanthin A.
[0090] <(j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives> <<Cis-type fucoxanthinol>> Cis-type fucoxanthinol consists of a polyene chain with nine conjugated double bonds and an allene structure, and end groups attached to both ends. In this specification, isomers containing at least one cis-type conjugated double bond are referred to as cis-type fucoxanthinol, and isomers in which all are trans-type are referred to as all-trans-type fucoxanthinol.
[0091] ≪Cis-type fucoxanthinol derivatives≫ Examples of cis-type fucoxanthinol derivatives include lipid esters of cis-type fucoxanthinol, glycosides of cis-type fucoxanthinol, fatty acid glycosides of cis-type fucoxanthinol, aliphatic ethers of cis-type fucoxanthinol, and sulfate esters of cis-type fucoxanthinol.
[0092] ・Lipid esters of cis-type fucoxanthinol The lipids (fatty acids) in the lipid esters of cis-type fucoxanthinol are the same lipids as those in the lipid esters of cis-type lutein described above. The lipid esters of cis-type fucoxanthinol may be composed of a mixture of multiple lipid esters. In the mixture, the molar ratio of lipids to cis-type fucoxanthinol is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4. For example, in a mixture of lipid esters of cis-type fucoxanthinol, the molar ratio of palmitic acid, stearic acid, elaidic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and docosahexaenoic acid to cis-type fucoxanthinol is preferably 0.0001 to 4, more preferably 0.001 to 4, even more preferably 0.01 to 4, and particularly preferably 0.02 to 4.
[0093] ・Cis-type fucoxanthinol glycosides The glycosides in cis-type fucoxanthinol glycosides include the same glycosides as those in cis-type lutein glycosides described above. The cis-type fucoxanthinol glycoside may be composed of a mixture of multiple cis-type fucoxanthinol glycosides. In such a mixture, the molar ratio of the glycoside to cis-type fucoxanthinol is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10. For example, in a mixture of cis-type fucoxanthinol glycosides, the molar ratio of fucose, xylose, lactose, and glucose to cis-type fucoxanthinol is preferably 0.001 to 600, more preferably 0.01 to 400, even more preferably 0.01 to 100, and particularly preferably 0.01 to 10.
[0094] • Fatty acid glycosides of cis-fucoxanthinol Examples of fatty acid glycosides in cis-fucoxanthinol fatty acid glycosides include glucose fatty acid esters. The fatty acid glycoside of cis-fucoxanthinol may be composed of a mixture of multiple fatty acid glycosides of cis-fucoxanthinol.
[0095] Aliphatic ethers of cis-fucoxanthinol Examples of aliphatic ethers of cis-fucoxanthinol include generally known aliphatic ethers of cis-fucoxanthinol. An aliphatic ether of cis-fucoxanthinol may be composed of a mixture of multiple aliphatic ethers of cis-fucoxanthinol.
[0096] • Sulfate esters of cis-type fucoxanthinol Examples of sulfate esters of cis-type fucoxanthinol include generally known sulfate esters of cis-type fucoxanthinol. Sulfate esters of cis-type fucoxanthinol may be composed of a mixture of multiple sulfate esters of cis-type fucoxanthinol.
[0097] (a) cis-type lutein, (b) cis-type zeaxanthin, (c) cis-type meso-zeaxanthin, (d) cis-type astaxanthin, (e) cis-type β-cryptoxanthin, (f) cis-type capsanthin, (g) cis-type capsorbin, (h) cis-type fucoxanthin, (i) cis-type amarouciaxanthin, and (j) cis-type fucoxanthinol have a cyclic group with one hydroxyl group at either end of a polyene chain consisting of a conjugated double bond, and therefore the molecule as a whole has 1 to 2 hydroxyl groups. For this reason, mono-forms, di-forms, and mixtures thereof may exist, including monoesters and diesters and mixtures thereof, monoglycosides, diglycosides and mixtures thereof, monolipid glycosides, dilipid glycosides and mixtures thereof, monoaliphatic ethers, dialiphatic ethers and mixtures thereof, sulfate monoesters, sulfate diesters and mixtures thereof. In this specification, mono-isomers, di-isomers, and mixtures thereof may be used. In the case of mixtures of mono-isomers and di-isomers, the mixing ratio (mono-isomer:di-isomer) is preferably 1:100 to 100:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, particularly preferably 1:16 to 16:1, and most preferably in the range of 1:10 to 10:1. The relative abundance of mono-isomers, di-isomers, and mixtures thereof can be confirmed by high-performance liquid chromatography (HPLC) or thin-layer chromatography (TLC).
[0098] (Methods for producing the compounds) (a) cis-type lutein, (b) cis-type zeaxanthin, (c) cis-type meso-zeaxanthin, (d) cis-type astaxanthin, (e) cis-type β-cryptoxanthin, (f) cis-type capsanthin, (g) cis-type capsorbin, (h) cis-type fucoxanthin, (i) cis-type amarociaxanthin, and (j) cis-type fucoxanthinol can be produced by methods known from the literature. For example, they can be produced by the method described in International Publication No. 2023 / 120618 or by the method described in Reference 1 (Journal of the Japan Society for Food Engineering, Vol. 21, No. 1, pp. 1-10, Mar. 2020). Specifically, examples include methods of dissolving trans lutein, trans zeaxanthin, trans meso-zeaxanthin, trans astaxanthin, trans β-cryptoxanthin, trans capsanthin, trans capsorbin, trans fucoxanthin, trans amarausciaxanthin, or trans fucoxanthinol in organic solvents (dichloromethane, chloroform, acetone, ethyl acetate, etc.), vegetable oils (sesame oil, mustard oil, etc.), or supercritical carbon dioxide, and then heat-treating the solution; and methods of using cis-type isomerization catalysts such as isothiocyanates, polysulfides, or iodine.
[0099] Cis-type lutein derivatives, cis-type zeaxanthin derivatives, cis-type meso-zeaxanthin derivatives, cis-type astaxanthin derivatives, cis-type β-cryptoxanthin derivatives, cis-type capsanthin derivatives, cis-type capsorbin derivatives, cis-type fucoxanthin derivatives, cis-type amarouciaxanthin derivatives, and cis-type fucoxanthinol derivatives can be produced by generally known methods, for example, by converting trans-type lutein, etc., into lipid esters of trans-type lutein, glycosides of trans-type lutein, fatty acid glycosides of trans-type lutein, aliphatic ethers of trans-type lutein, or sulfate esters of trans-type lutein, and then isomerizing them using the method described in Reference 1 above. Isomerization from trans-type to cis-type can be confirmed by HPLC. Furthermore, commercially available trans lutein, trans zeaxanthin, trans meso-zeaxanthin, trans astaxanthin, trans β-cryptoxanthin, trans capsanthin, trans capsorbin, trans fucoxanthin, trans amarociaxanthin, and trans fucoxanthinol can be used. Trans lutein, trans zeaxanthin, trans meso-zeaxanthin, trans astaxanthin, trans β-cryptoxanthin, trans capsanthin, trans capsorbin, trans fucoxanthin, trans amarociaxanthin, and trans fucoxanthinol can be obtained as chemically synthesized products, naturally derived products (for example, microalgae such as the green alga Haematococcus, yeasts such as the red yeast Phaffia, crustaceans of arthropods such as shrimp, krill, crabs, and Daphnia, and their extracts), or mixtures thereof.
[0100] For example, (a) lipid esters of cis-type lutein, (b) lipid esters of cis-type zeaxanthin, (c) lipid esters of cis-type meso-zeaxanthin, (d) lipid esters of cis-type astaxanthin, (e) lipid esters of cis-type β-cryptoxanthin, (f) lipid esters of cis-type capsanthin, (g) lipid esters of cis-type capsorbin, (h) lipid esters of cis-type fucoxanthin, (i) lipid esters of cis-type amarauciaxanthin, and (j) lipid esters of cis-type fucoxanthinol are trans-type lutein, trans-type zeaxanthin, trans-type meso-zeaxanthin, trans-type astaxanthin, trans-type β-cryptoxanthin, trans-type capsanthin, trans-type capsanthin The following can be produced by reacting sorbin, trans fucoxanthin, trans amarouciaxanthin, or trans fucoxanthinol with lipids to obtain (a) lipid esters of cis lutein, (b) lipid esters of cis zeaxanthin, (c) lipid esters of cis meso-zeaxanthin, (d) lipid esters of cis astaxanthin, (e) lipid esters of cis β-cryptoxanthin, (f) lipid esters of cis capsanthin, (g) lipid esters of cis capsorbin, (h) lipid esters of cis fucoxanthin, (i) lipid esters of cis amarouciaxanthin, or (j) lipid esters of cis fucoxanthinol, and isomerizing them according to the method described in Reference 1.
[0101] For example, (a) glycosides of cis lutein, (b) glycosides of cis zeaxanthin, (c) glycosides of cis meso-zeaxanthin, (d) glycosides of cis astaxanthin, (e) glycosides of cis β-cryptoxanthin, (f) glycosides of cis capsanthin, (g) glycosides of cis capsorbin, (h) glycosides of cis fucoxanthin, (i) glycosides of cis amarauciaxanthin, and (j) glycosides of cis fucoxanthinol are trans lutein, trans zeaxanthin, trans meso-zeaxanthin, trans astaxanthin, trans β-cryptoxanthin, trans capsanthin, trans capso Rubin, trans fucoxanthin, trans amarouciaxanthin, or trans fucoxanthinol can be reacted with glycosides to obtain (a) a glycoside of cis lutein, (b) a glycoside of cis zeaxanthin, (c) a glycoside of cis meso-zeaxanthin, (d) a glycoside of cis astaxanthin, (e) a glycoside of cis β-cryptoxanthin, (f) a glycoside of cis capsanthin, (g) a glycoside of cis capsorbin, (h) a glycoside of cis fucoxanthin, (i) a glycoside of cis amarouciaxanthin, or (j) a glycoside of cis fucoxanthin, which can then be isomerized by the method described in Reference 1.
[0102] For example, (a) fatty acid glycosides of cis lutein, (b) fatty acid glycosides of cis zeaxanthin, (c) fatty acid glycosides of cis meso-zeaxanthin, (d) fatty acid glycosides of cis astaxanthin, (e) fatty acid glycosides of cis β-cryptoxanthin, (f) fatty acid glycosides of cis capsanthin, (g) fatty acid glycosides of cis capsorbin, (h) fatty acid glycosides of cis fucoxanthin, (i) fatty acid glycosides of cis amarauciaxanthin, and (j) fatty acid glycosides of cis fucoxanthinol are trans lutein, trans zeaxanthin, trans meso-zeaxanthin, trans astaxanthin, trans β-cryptoxanthin, trans capsanthin, and trans capsol By reacting vin, trans fucoxanthin, trans amarouciaxanthin, or trans fucoxanthinol with fatty acid glycosides, (a) fatty acid glycosides of cis lutein, (b) fatty acid glycosides of cis zeaxanthin, (c) fatty acid glycosides of cis meso-zeaxanthin, (d) fatty acid glycosides of cis astaxanthin, (e) fatty acid glycosides of cis β-cryptoxanthin, (f) fatty acid glycosides of cis capsanthin, (g) fatty acid glycosides of cis capsorbin, (h) fatty acid glycosides of cis fucoxanthin, (i) fatty acid glycosides of cis amarouciaxanthin, or (j) fatty acid glycosides of cis fucoxanthinol can be produced by isomerizing these glycosides using the method described in Reference 1.
[0103] For example, (a) aliphatic ether of cis lutein, (b) aliphatic ether of cis zeaxanthin, (c) aliphatic ether of cis meso-zeaxanthin, (d) aliphatic ether of cis astaxanthin, (e) aliphatic ether of cis β-cryptoxanthin, (f) aliphatic ether of cis capsanthin, (g) aliphatic ether of cis capsorbin, (h) aliphatic ether of cis fucoxanthin, (i) aliphatic ether of cis amoruciaxanthin, and (j) aliphatic ether of cis fucoxanthinol are trans lutein, trans zeaxanthin, trans meso-zeaxanthin, trans astaxanthin, trans β-cryptoxanthin, trans capsanthin, trans capsorbin It can be produced by reacting trans fucoxanthin, trans amarouciaxanthin, or trans fucoxanthinol with an aliphatic ether to obtain (a) an aliphatic ether of cis lutein, (b) an aliphatic ether of cis zeaxanthin, (c) an aliphatic ether of cis meso-zeaxanthin, (d) an aliphatic ether of cis astaxanthin, (e) an aliphatic ether of cis β-cryptoxanthin, (f) an aliphatic ether of cis capsanthin, (g) an aliphatic ether of cis capsorbin, (h) an aliphatic ether of cis fucoxanthin, (i) an aliphatic ether of cis amarouciaxanthin, or (j) an aliphatic ether of cis fucoxanthinol, and isomerizing them according to the method described in Reference 1 above.
[0104] For example, (a) sulfated glycoside of cis-type lutein, (b) sulfated glycoside of cis-type zeaxanthin, (c) sulfated glycoside of cis-type meso-zeaxanthin, (d) sulfated glycoside of cis-type astaxanthin, (e) sulfated glycoside of cis-type β-cryptoxanthin, (f) sulfated glycoside of cis-type capsanthin, (g) sulfated glycoside of cis-type capsorbin, (h) sulfated glycoside of cis-type fucoxanthin, (i) sulfated glycoside of cis-type amarauciaxanthin, and (j) sulfated glycoside of cis-type fucoxanthinol are trans-type lutein, trans-type zeaxanthin, trans-type meso-zeaxanthin, trans-type astaxanthin, trans-type β-cryptoxanthin, trans-type capsanthin, and trans-type capsol By reacting vin, trans fucoxanthin, trans amarouciaxanthin, or trans fucoxanthinol with a sulfated glycoside, (a) a sulfated glycoside of cis lutein, (b) a sulfated glycoside of cis zeaxanthin, (c) a sulfated glycoside of cis meso-zeaxanthin, (d) a sulfated glycoside of cis astaxanthin, (e) a sulfated glycoside of cis β-cryptoxanthin, (f) a sulfated glycoside of cis capsanthin, (g) a sulfated glycoside of cis capsorbin, (h) a sulfated glycoside of cis fucoxanthin, (i) a sulfated glycoside of cis amarouciaxanthin, or (j) a sulfated glycoside of cis fucoxanthinol can be produced by isomerizing these by the method described in Reference 1.
[0105] The composition of this embodiment may also be a combination of (a) cis-type lutein and a derivative of cis-type lutein, (b) cis-type zeaxanthin and a derivative of cis-type zeaxanthin, (c) cis-type meso-zeaxanthin and a derivative of cis-type meso-zeaxanthin, (d) cis-type astaxanthin and a derivative of cis-type astaxanthin, (e) cis-type β-cryptoxanthin and a derivative of cis-type β-cryptoxanthin, (f) cis-type capsanthin and a derivative of cis-type capsanthin, (g) cis-type capsorbin and a derivative of cis-type capsorbin, (h) cis-type fucoxanthin and a derivative of cis-type fucoxanthin, (i) cis-type amarouciaxanthin and a derivative of cis-type amarouciaxanthin, and (j) cis-type fucoxanthinol and a derivative of cis-type fucoxanthinol. As described above, by using each free form in combination with its corresponding derivative, the isomerization of each free form to the trans form can be further suppressed, storage stability can be further improved, and administration for a longer period can be made possible. When using each free form in combination with its corresponding derivative, the content of the corresponding derivative relative to each free form (molar ratio) is preferably 0.05 to 1000, more preferably 0.1 to 100, and even more preferably 1 to 10.
[0106] The composition of this embodiment may contain all-trans xanthophylls and all-trans xanthophyll derivatives such as all-trans lutein, all-trans lutein derivatives, all-trans zeaxanthin, all-trans zeaxanthin derivatives, all-trans meso-zeaxanthin, all-trans meso-zeaxanthin derivatives, all-trans astaxanthin, all-trans astaxanthin derivatives, all-trans β-cryptoxanthin, all-trans β-cryptoxanthin derivatives, all-trans capsanthin, all-trans capsanthin derivatives, all-trans capsorbin, all-trans capsorbin derivatives, all-trans fucoxanthin, all-trans fucoxanthin derivatives, all-trans amarouciaxanthin, all-trans amarouciaxanthin derivatives, and all-trans fucoxanthinol, but the all-xanthophyll derivatives of the composition of this embodiment may contain (a) cis-lutein and / or cis-lutein (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives, (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives, (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives, (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives, (f) cis-type capsanthin and / or cis-type capsanthin derivatives, (g) cis-type capsorbin and / or The total proportion of cis-type capsorbin derivatives, (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives, (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives, and (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives is preferably 30% or more, more preferably 35% or more, even more preferably 40% or more, and particularly preferably 45% or more.
[0107] The mitochondrial function-improving composition of this embodiment is preferably used to improve or prevent the progression of insulin resistance caused by obesity. The insulin resistance is caused by, for example, sarcopenic obesity, subcutaneous fat obesity, or visceral fat obesity. The improvement or prevention of the progression of insulin resistance is achieved, for example, by improving glucose uptake in skeletal muscle and improving blood glucose levels.
[0108] <Optional ingredients> The composition of this embodiment may also contain any other components other than (a) cis-type lutein and / or cis-type lutein derivatives, (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives, (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives, (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives, (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives, (f) cis-type capsanthin and / or cis-type capsanthin derivatives, (g) cis-type capsorbin and / or cis-type capsorbin derivatives, (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives, (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives, and (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives. Optional ingredients include antioxidants and additives.
[0109] <<Antioxidants>> Examples of antioxidants include compounds having a phenolic hydroxyl group; amine compounds such as phenylenediamines like diphenyl-p-phenylenediamine and 4-amino-p-diphenylamine; ascorbic acid; and oil-soluble derivatives of erythorbic acid. Specifically, examples of compounds having a phenolic hydroxyl group include guaiac fat; nordihydroguaiaretic acid (NDGA); gallic acid esters such as propyl gallate, butyl gallate, and octyl gallate; BHT (butylated hydroxytoluene); BHA (butylated hydroxyanisole); tocopherols (vitamin E; hereafter, VE) such as mixed tocopherols; tocotrienols and bisphenols. Among the above, tocopherols and oil-soluble derivatives of ascorbic acid are preferred as antioxidants.
[0110] Additives: Examples of additives include solvents, solubilizers, lubricants, emulsifiers, isotonic agents, preservatives, surfactants, pH adjusters, buffers, excipients, sweeteners, or flavorings.
[0111] • Solvents include monoglycerides, diglycerides, and triglycerides, specifically olive oil, camellia oil, macadamia nut oil, castor oil, avocado oil, evening primrose oil, turtle oil, corn oil, mink oil, rapeseed oil, egg yolk oil, sesame oil, peach kernel oil, wheat germ oil, sasanqua oil, linseed oil, safflower oil, cottonseed oil, elm oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, cinnamon oil, Japanese tung oil, jojoba oil, wheat germ oil, glyceryl trioctanoate, glyceryl triisopalmitate, salad oil, safflower oil, palm oil, coconut oil, peanut oil, almond oil, hazelnut oil, walnut oil, grapeseed oil, etc.
[0112] Lubricants include, for example, gum arabic powder, cocoa butter, carnauba wax, carmellose calcium, carmellose sodium, caropeptide, hydrated silicon dioxide, dried aluminum hydroxide gel, glycerin, magnesium silicate, light anhydrous silicic acid, light liquid paraffin, crystalline cellulose, hydrogenated oil, synthetic aluminum silicate, sesame oil, wheat starch, bleached beeswax, magnesium oxide, dimethylpolysiloxane, potassium sodium tartrate, sucrose fatty acid ester, glycerin fatty acid ester, silicone resin, aluminum hydroxide gel, stearyl alcohol, stearic acid, aluminum stearate, and stearate. Examples include calcium, polyoxyl stearate, magnesium stearate, cetanol, gelatin, talc, magnesium carbonate, precipitated calcium carbonate, corn starch, lactose, hard fat, sucrose, potato starch, hydroxypropyl cellulose, fumaric acid, sodium stearyl fumarate, polyethylene glycol, polyoxyethylene polyoxypropylene glycol, polysorbate, beeswax, magnesium aluminometasilicate, methylcellulose, Japanese wax, glyceryl monostearate, sodium lauryl sulfate, calcium sulfate, magnesium sulfate, liquid paraffin, and phosphoric acid.
[0113] • Solubilizers: Examples of solubilizers include nonionic surfactants such as polyoxyethylene sorbitan monooleate (polysorbate 80), polyoxyethylene monostearate, and polyoxyethylene hydrogenated castor oil, as well as polyethylene glycol.
[0114] Examples of emulsifiers include sucrose fatty acid esters, polysorbates, polyglycerol fatty acid esters, lecithin, and lysolecithin.
[0115] Isotonic agents include sugars such as sorbitol, glucose, and mannitol, polyhydric alcohols such as glycerin and propylene glycol, and sodium chloride.
[0116] Examples of preservatives include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride; parahydroxybenzoic acid esters such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate; benzyl alcohol, phenethyl alcohol, sorbic acid and their salts; thimerosal; chlorobutanol; and sodium dehydroacetate.
[0117] • Surfactants Examples of surfactants include sucrose fatty acid esters, propylene glycol esters, glycerin fatty acid esters, sorbitan fatty acid esters, dextrin, and reduced dextrin.
[0118] pH adjusters Examples of pH adjusters include hydrochloric acid, phosphoric acid, acetic acid, tartaric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium bicarbonate.
[0119] Buffering agents include phosphate buffers, tartrate buffers, amino acids, etc.
[0120] Excipients: Examples of excipients include lactose, sucrose, mannitol, corn starch, and crystalline cellulose.
[0121] By using an emulsified composition of the composition of this embodiment, isomerization to the trans isomer can be further suppressed, storage stability can be further improved, and administration over a longer period can be made possible. The emulsified composition may include: (a) cis-type lutein and / or cis-type lutein derivatives, (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives, (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives, (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives, (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives, and (f) cis-type capsanthin and / or cis-type capsanthin derivatives. It is preferable that the emulsified composition contains any of the following compounds: (g) cis-type capsorbin and / or cis-type capsorbin derivatives, (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives, (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives, and (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives, and at least one compound selected from the group consisting of polyglycerin fatty acid esters and sucrose fatty acid esters. Furthermore, it is preferable that the total content of compounds (a) to (j) relative to the total cis-type and trans-type compounds in the emulsified composition is 40% by mass or more.
[0122] [Applications] The composition of this embodiment can be used in foods, beverages, functional foods, nutritional supplements, pharmaceuticals, quasi-drugs, cosmetics, veterinary drugs, pet food, feed, or animal feed. Its forms include tablets, capsules, eye drops, powders, and beverages.
[0123] (a) cis-type lutein and / or cis-type lutein derivatives, (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives, (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives, (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives, (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives, (f) cis-type capsanthin and / or cis-type capsanthin derivatives, The total content of (g) cis-type capsorbin and / or cis-type capsorbin derivatives, (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives, (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives, and (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives is preferably 0.5 to 40% by mass, more preferably 1 to 30% by mass, and even more preferably 5 to 20% by mass, relative to the entire product.
[0124] The composition of this embodiment can be formulated with commonly known additives to suit its purpose and can be in the form of oil, powder, emulsion, etc.
[0125] [Other embodiments] (1) In one embodiment, the present invention provides the use of cis-type xanthophyll in the production of a composition for improving mitochondrial function. (2) In one embodiment, the present invention provides the use of one or more of the following (a) to (j) cis-type xanthophyll in the production of a composition for improving mitochondrial function. (a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives (3) In one embodiment, the present invention provides the use of cis-xanthophyll for improving mitochondrial function. (4) In one embodiment, the present invention provides the use of cis-xanthophyll which is one or more of the following (a) to (j) for improving mitochondrial function.(a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives (5) In one embodiment, the present invention provides a method for improving or preventing the progression of insulin resistance due to obesity, comprising orally administering a pharmaceutical composition containing a composition for improving mitochondrial function. (6) In one embodiment, the present invention provides a method for improving or preventing the progression of insulin resistance due to obesity, comprising orally administering a pharmaceutical composition containing a composition for improving mitochondrial function containing one or more of the following (a) to (j).(a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives (7) In one embodiment, the present invention provides a method for improving or preventing the progression of insulin resistance caused by obesity of any type, such as sarcopenic obesity, subcutaneous fat obesity, or visceral fat obesity, comprising orally administering a pharmaceutical composition comprising a composition for improving mitochondrial function. (8) In one embodiment, the present invention provides a method for improving or preventing the progression of insulin resistance caused by obesity of any type, such as sarcopenic obesity, subcutaneous fat obesity, or visceral fat obesity, comprising orally administering a pharmaceutical composition comprising a composition for improving mitochondrial function comprising a composition containing one or more of the following (a) to (j).(a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives (9) In one embodiment, the present invention provides a method for improving blood glucose levels, which includes orally administering a pharmaceutical composition containing a mitochondrial function improving composition, thereby improving glucose uptake in skeletal muscle. (10) In one embodiment, the present invention provides a cis-xanthophyll for orally administering a pharmaceutical composition containing a mitochondrial function improving composition. (11) In one embodiment, the present invention provides a cis-xanthophyll which is one or more of the following (a) to (j) for orally administering a pharmaceutical composition containing a mitochondrial function improving composition. (a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives.
[0126] The present invention will be described in more detail below with reference to examples, reference examples, comparative examples, and test examples, but the present invention is not limited thereto.
[0127] (Reference Example 1) (Preparation of cis-type astaxanthin fatty acid ester) As a method for preparing cis-type astaxanthin fatty acid ester, an astaxanthin extract derived from Haematococcus algae (AstaREAL L10, hereinafter referred to as "astaxanthin ester A") was used. Specifically, 25 g of astaxanthin ester A was weighed into a 100 g glass container, the headspace of the container was replaced with nitrogen, and it was immediately sealed. After heating this container in an oil bath at 180°C for 15 minutes, it was immediately cooled with ice to obtain cis-type astaxanthin ester A. The obtained cis-type astaxanthin ester A was hydrolyzed with cholesterol esterase (Fujifilm Wako Pure Chemical Industries, Japan), dissolved in a mixture of hexane and ethyl acetate (9:1, v / v) to obtain free astaxanthin isomer A. Astaxanthin isomer A was detected at 470 nm using an HPLC-photodiode array detector (SPD-M20A, Shimadzu Corporation, Japan). The analytical conditions were set as follows, according to Reference 2 (Honda et al., Food Chem, 2021, 361:130119): <Analytical conditions> Stationary phase: Two Phenomenex silica gel columns connected in series (Luna 5 μm Silica (2), 150 mm × 4.6 mm, 100 Å, Phenomenex Inc., USA); Column temperature: 40°C Mobile phase: Mixture of hexane / ethyl acetate / acetone (75:23:2, v / v / v); Mobile phase flow rate: 1.2 mL / min
[0128] The resulting chromatogram is shown in Figure 1 (the composition of each peak is shown in the figure; * indicates an unidentified cis-astaxanthin isomer). This process yielded a composition containing 58.8% cis-astaxanthin.
[0129] (Test Example 1) (Rat administration test of cis-type astaxanthin fatty acid ester) The astaxanthin ester obtained above was suspended in soybean oil (Fujifilm Wako Pure Chemical Industries, Japan) and administered to male Slc / SD rats (Nippon SLC Co., Ltd. (Shizuoka Prefecture, Japan)). The rats were introduced at 12 weeks of age and housed under conditions of 23±5°C, 55±25% humidity, and a 12-hour light-dark cycle. During the acclimatization period and the test period, they were given drinking water and a standard laboratory diet (AIN93M; Oriental Yeast Co., Ltd., Tokyo, Japan) that did not contain carotenoids. After 7 days of acclimatization, a single oral administration test was performed using soybean oil prepared to contain 100 mg / kg body weight as total astaxanthin. Blood was collected before administration of the test diet and 1, 3, 6, 9, 10.5, 12, and 24 hours after administration. Plasma samples were prepared by centrifugation from heparin-treated blood samples. The obtained plasma was extracted from the solvent phase with hexane and acetone according to Reference 3 (Honda et al., Food Chem, 2021, 361:130119), dissolved in a mixture of hexane and ethyl acetate (9:1, v / v), and subjected to HPLC analysis under the same conditions as described above. The results are shown in Table 1 and Figure 2.
[0130]
[0131] Based on these results, the maximum plasma concentration (Cmax) and area under the blood concentration curve (AUC) of the free cis-astaxanthin isomer in a non-compartment model can be determined from 0 to 24 hours. 0-24h The values calculated using the following method were 11.1 ± 1.0 ng / mL (Tmax: 9.0 hours) and 146.7 ± 13.7 ng・h / mL, respectively. From these results, it was found that when cis-type astaxanthin ester is ingested, it is significantly converted to free cis-type astaxanthin in the blood.
[0132] (Test Example 2) (Evaluation of cis- and trans-astaxanthin using a skeletal muscle cell model) To evaluate the effects of trans- and cis-astaxanthin on the maturation period of skeletal muscle, we used the in vitro cell test system described in Reference 1 (Journal of the Japan Society for Food Engineering, Vol. 21, No. 1, pp. 1-10, Mar. 2020). Specifically, we aimed to investigate how cis-astaxanthin affects differentiation and function in muscle cells using the mouse-derived myoblast cell line C2C12. After differentiating C2C12 cells into muscle cells (myotube) as described in Reference 4 (J Cachexia Sarcopenia Muscle, 2020, 11(1), 241-258), we added trans- and cis-astaxanthin and examined the effects on differentiated muscle cells (Figure 3). In this experiment, C2C12 cells were grown in growth medium (DMEM + 10% FBS + 1% Penicillin-Streptomycin) until 70-80% conformation was achieved. They were then cultured for 7 days in differentiation medium (DMEM + 2% Horse serum + 1% Penicillin-Streptomycin) to differentiate them into muscle cells. Afterward, 5 μM or 50 μM cis-astaxanthin or trans-astaxanthin was added, and after confirming that no crystals or other precipitates formed, the cells were cultured for 24 hours, followed by RNA extraction and qPCR.
[0133] As a result, the group treated with cis-astaxanthin showed a dose-dependent increase in the mRNA expression levels of PGC1α and PPARγ. In the group treated with trans-astaxanthin, the mRNA expression levels of PGC1α and PPARγ tended to increase, but the effect was weaker compared to the cis-astaxanthin group. The difference in activity was approximately 10 times. Furthermore, Nampt and NAD, the rate-limiting enzymes in the NAD resynthesis pathway, were also investigated. + The mRNA expression level of the histone deacetylase Sirt1 also increased in a dose-dependent manner with cis-astaxanthin, but the difference was not statistically significant. These results indicate that cis-astaxanthin has significantly greater positive effects on lipid metabolism and mitochondrial biosynthesis compared to trans-astaxanthin.
[0134] (Test Example 3) (Test Title) To investigate the in vivo effects of cis-astaxanthin, the effects on motor function and metabolic changes were evaluated using mice. Six 5-week-old C57BL / 6NCrSlc mice from each group were orally administered 30 μmol three times a week, suspended in soybean oil to a clear solution of free trans- or cis-astaxanthin (a mixture). The administration period was 10 weeks. After evaluating muscle function at the end of administration, the mice were euthanized, the gastrocnemius muscle was excised, mRNA was extracted, and qPCR was performed. Changes in individual expression levels were compared with those in the soybean oil medium, and the average values were obtained. A study similar to this one, described in reference 5 (Y. Nishida et al., J Cachexia Sarcopenia Muscle, 2020, 11(1), 241-258), involved administering trans-type astaxanthin derived from Haematococcus algae to C57BL / 6J mice fed a high-fat diet. This report showed increased mitochondrial count and mitochondrial function, as well as increased mRNA expression levels related to the electron transport chain and catabolic metabolism of fatty acids and carbohydrates in the gastrocnemius muscle, along with increased protein levels. Improvements in skeletal muscle redness and endurance were also reported. Therefore, we compared the superiority of the trans-type astaxanthin compared to the trans-type in gene expression in the gastrocnemius muscle after administration. As shown in Figure 4, compared to administration of trans astaxanthin, mRNA expression levels of Ndufa9 (a protein that constitutes mitochondrial electron transport chain complex I) and Sdha (a gene that constitutes complex II, which plays a central role in mitochondrial energy metabolism (TCA cycle and electron transport chain)) were elevated with cis astaxanthin compared with trans astaxanthin. In relation to mitochondrial metabolism, mRNA expression levels of genes such as Pdk4, which promotes fatty acid utilization in mitochondria, and Mcad, which is involved in the initial stages of fatty acid β-oxidation within mitochondria, were similarly elevated with cis astaxanthin compared with trans astaxanthin (Figure 4). Next, we focused on muscle fiber types, which directly demonstrate mitochondrial function. Skeletal muscle fibers can be broadly divided into three types based on differences in myosin heavy chain (MyHC). These are Type I (slow-twitch muscle), which is rich in endurance; Type IIx / b (fast-twitch muscle), which is rich in explosive power; and Type IIa, which exhibits properties intermediate between these two types.MyHC isoforms are indicators of muscle fiber type and strongly correlate with mitochondrial activity. Specifically, it is widely known that the amount of mitochondria is highest in Type I (slow-twitch muscle), followed by Type IIa, and lowest in Type IIx / b (fast-twitch muscle). It is well known that the properties of these muscle fibers in the gastrocnemius muscle change depending on exercise and daily energy status. As shown in reference 5, previous findings on the administration of astaxanthin derived from Haematococcus algae have shown that it slightly increases the mRNA expression of MyHCIa, but rather increases MyHCIIa and MyHCIIx. As shown in Figure 5, when comparing the mRNA expression of MyHC isoforms constituting the muscle fibers of mouse gastrocnemius muscle after administration of cis and trans astaxanthin, it was shown that MyHCIIa mRNA expression was slightly elevated with cis astaxanthin compared to trans astaxanthin. Notably, the cis-astaxanthin administration group actually enhanced MyHCIa expression. Furthermore, the trans-astaxanthin administration group showed increased mRNA expression of MyHCIIb and MyHCIIx, which constitute Type IIx / b, a type with fewer mitochondria, while the cis-astaxanthin group did not show this increased mRNA expression. These results indicate that cis-astaxanthin administration transformed skeletal muscle into Type I (slow-twitch muscle) with higher mitochondrial activity, and from the perspective of mitochondrial activation, the cis-astaxanthin administration group showed higher activity. To evaluate muscle function, these mice were measured for grip strength and maximum treadmill distance. As shown in Figure 6, the cis-astaxanthin administration group showed a tendency for increased muscle strength and treadmill distance, which indicate endurance, compared to the trans-astaxanthin group. This result suggests that cis-astaxanthin improved skeletal muscle function through enhanced mitochondrial function compared to trans-astaxanthin.
[0135] While preferred embodiments of the present invention have been described above, the present invention is not limited to these embodiments. Additions, omissions, substitutions, and other modifications are possible without departing from the spirit of the invention. The present invention is not limited by the foregoing description, but only by the scope of the appended claims.
Claims
1. A composition for improving mitochondrial function, containing cis-type xanthophyll.
2. The cis-type xanthophyll is one or more of the following (a) to (j), the composition for improving mitochondrial function according to claim 1. (a) cis-type lutein and / or cis-type lutein derivatives (b) cis-type zeaxanthin and / or cis-type zeaxanthin derivatives (c) cis-type meso-zeaxanthin and / or cis-type meso-zeaxanthin derivatives (d) cis-type astaxanthin and / or cis-type astaxanthin derivatives (e) cis-type β-cryptoxanthin and / or cis-type β-cryptoxanthin derivatives (f) cis-type capsanthin and / or cis-type capsanthin derivatives (g) cis-type capsorbin and / or cis-type capsorbin derivatives (h) cis-type fucoxanthin and / or cis-type fucoxanthin derivatives (i) cis-type amarouciaxanthin A and / or cis-type amarouciaxanthin A derivatives (j) cis-type fucoxanthinol and / or cis-type fucoxanthinol derivatives 3. The composition for improving mitochondrial function according to claim 2, wherein the cis-lutein derivative comprises one or more cis-lutein derivatives selected from the group consisting of lipid esters of cis-lutein, glycosides of cis-lutein, fatty acid glycosides of cis-lutein, aliphatic ethers of cis-lutein, and sulfate esters of cis-lutein.
4. The composition for improving mitochondrial function according to claim 2, wherein the cis-type lutein derivative comprises a lipid ester of cis-type lutein.
5. The composition for improving mitochondrial function according to claim 2, wherein the cis-type lutein derivative comprises a lipid ester of cis-type lutein with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
6. The composition for improving mitochondrial function according to claim 2, wherein the cis-type zeaxanthin derivative comprises one or more cis-type zeaxanthin derivatives selected from the group consisting of lipid esters of cis-type zeaxanthin, glycosides of cis-type zeaxanthin, fatty acid glycosides of cis-type zeaxanthin, aliphatic ethers of cis-type zeaxanthin, and sulfate esters of cis-type zeaxanthin.
7. The composition for improving mitochondrial function according to claim 2, wherein the cis-type zeaxanthin derivative comprises a lipid ester of cis-type zeaxanthin.
8. The composition for improving mitochondrial function according to claim 2, wherein the cis-type zeaxanthin derivative comprises a lipid ester of cis-type zeaxanthin with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
9. The composition for improving mitochondrial function according to claim 2, wherein the cis-astaxanthin derivative comprises one or more cis-astaxanthin derivatives selected from the group consisting of lipid esters of cis-astaxanthin, glycosides of cis-astaxanthin, fatty acid glycosides of cis-astaxanthin, aliphatic ethers of cis-astaxanthin, and sulfate esters of cis-astaxanthin.
10. The composition for improving mitochondrial function according to claim 2, wherein the cis-type astaxanthin derivative comprises a lipid ester of cis-type astaxanthin.
11. The composition for improving mitochondrial function according to claim 2, wherein the cis-type astaxanthin derivative comprises a lipid ester of cis-type astaxanthin with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
12. The composition for improving mitochondrial function according to claim 2, wherein the cis-type β-cryptoxanthin comprises one or more cis-type β-cryptoxanthin selected from the group consisting of lipid esters of cis-type β-cryptoxanthin, glycosides of cis-type β-cryptoxanthin, fatty acid glycosides of cis-type β-cryptoxanthin, aliphatic ethers of cis-type β-cryptoxanthin, and sulfate esters of cis-type β-cryptoxanthin.
13. The composition for improving mitochondrial function according to claim 2, wherein the cis-type β-cryptoxanthin comprises a lipid ester of cis-type β-cryptoxanthin.
14. The composition for improving mitochondrial function according to claim 2, wherein the cis-type β-cryptoxanthin comprises a lipid ester of cis-type β-cryptoxanthin with one or more fatty acids selected from the group consisting of palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid.
15. A composition for improving mitochondrial function according to claim 1 or 2, used for improving or preventing the progression of insulin resistance caused by obesity.
16. The mitochondrial function improving composition according to claim 15, wherein the insulin resistance is due to any of sarcopenic obesity, subcutaneous fat obesity, or visceral fat obesity.
17. The composition for improving mitochondrial function according to claim 15, wherein the improvement or prevention of progression of insulin resistance is due to improved glucose uptake in skeletal muscle and an improvement in blood glucose levels.
18. A food, pharmaceutical, or cosmetic containing the mitochondrial function improving composition described in claim 1.
19. A method for producing a food, pharmaceutical, or cosmetic product, comprising the step of producing the mitochondrial function improving composition described in claim 1.
